DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

14 Drugs in Development

14 Drugs in Development

DIGITAL CONTENT

11 NEWS #PharmaBuzz

media
11 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

14DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Plx-9486, 2roq545lag, Cgt9486, Plx 9486 [who-dd], 4,5-dimethyl-n-(2-phenyl-1h-pyrrolo[2,3-b]pyridin-5-yl)-1h-pyrazole-3-carboxamide, 1616385-51-3

Molecular Formula

C₁₉H₁₇N₅O

Molecular Weight

331.4 g/mol

InChI Key

NVSHVYGIYPBTEZ-UHFFFAOYSA-N

FDA UNII

2ROQ545LAG

Bezuclastinib is an orally bioavailable protein tyrosine kinase inhibitor of mutated forms of the tumor-associated antigen mast/stem cell factor receptor c-Kit (SCFR), with potential antineoplastic activity. Upon oral administration, bezuclastinib binds to and inhibits specific c-Kit mutants. This may result in an inhibition of tumor cell proliferation in cancer cell types that overexpress these c-Kit mutations. c-Kit, a transmembrane protein and receptor tyrosine kinase, is overexpressed in solid tumors and hematological malignancies; it plays a key role in the regulation of cell differentiation and proliferation.

1 2D Structure

Bezuclastinib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

4,5-dimethyl-N-(2-phenyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazole-3-carboxamide

2.1.2 InChI

InChI=1S/C19H17N5O/c1-11-12(2)23-24-17(11)19(25)21-15-8-14-9-16(22-18(14)20-10-15)13-6-4-3-5-7-13/h3-10H,1-2H3,(H,20,22)(H,21,25)(H,23,24)

2.1.3 InChI Key

NVSHVYGIYPBTEZ-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC1=C(NN=C1C(=O)NC2=CN=C3C(=C2)C=C(N3)C4=CC=CC=C4)C

2.2 Other Identifiers

2.2.1 UNII

2ROQ545LAG

2.3 Synonyms

2.3.1 Depositor-Supplied Synonyms

1. Plx-9486

2. 2roq545lag

3. Cgt9486

4. Plx 9486 [who-dd]

5. 4,5-dimethyl-n-(2-phenyl-1h-pyrrolo[2,3-b]pyridin-5-yl)-1h-pyrazole-3-carboxamide

6. 1616385-51-3

7. 3,4-dimethyl-n-(2-phenyl-1h-pyrrolo(2,3-b)pyridin-5-yl)-1h-pyrazole-5-carboxamide

8. 3,4-dimethyl-n-(2-phenyl-1h-pyrrolo[2,3-b]pyridin-5-yl)-1h-pyrazole-5-carboxamide

9. Unii-2roq545lag

10. Bezuclastinib [inn]

11. Schembl15824576

12. Gtpl11868

13. Plx9486

14. Bdbm392363

15. Cgt-9486

16. Ex-a5975

17. Us10301280, Compound P-2007

18. Us10301280, Compound P-2164

19. Hy-145557

20. Cs-0376032

21. 3,4-dimethyl-n-(2-phenyl-1h- Pyrrolo[2,3-b]pyridin-5-yl)-1h- Pyrazole-5-carboxamide

22. Wej

2.4 Create Date

2014-07-14

3 Chemical and Physical Properties

Molecular Formula	C₁₉H₁₇N₅O
Molecular Weight	331.4 g/mol
XLogP3	3.2
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	3
Rotatable Bond Count	3
Exact Mass	331.14331018 g/mol
Monoisotopic Mass	331.14331018 g/mol
Topological Polar Surface Area	86.5 Å²
Heavy Atom Count	25
Formal Charge	0
Complexity	480
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1